258 related articles for article (PubMed ID: 31467059)
1. Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade.
Rauch DA; Conlon KC; Janakiram M; Brammer JE; Harding JC; Ye BH; Zang X; Ren X; Olson S; Cheng X; Miljkovic MD; Sundaramoorthi H; Joseph A; Skidmore ZL; Griffith O; Griffith M; Waldmann TA; Ratner L
Blood; 2019 Oct; 134(17):1406-1414. PubMed ID: 31467059
[TBL] [Abstract][Full Text] [Related]
2. PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma.
Jalili-Nik M; Soltani A; Mashkani B; Rafatpanah H; Hashemy SI
Int Immunopharmacol; 2021 Sep; 98():107870. PubMed ID: 34153661
[TBL] [Abstract][Full Text] [Related]
3. Rapid T-cell lymphoma progression associated with immune checkpoint inhibitors.
Ohmoto A; Fuji S
Expert Rev Hematol; 2023; 16(7):535-541. PubMed ID: 37191476
[TBL] [Abstract][Full Text] [Related]
4. PD-1
Kamada T; Togashi Y; Tay C; Ha D; Sasaki A; Nakamura Y; Sato E; Fukuoka S; Tada Y; Tanaka A; Morikawa H; Kawazoe A; Kinoshita T; Shitara K; Sakaguchi S; Nishikawa H
Proc Natl Acad Sci U S A; 2019 May; 116(20):9999-10008. PubMed ID: 31028147
[TBL] [Abstract][Full Text] [Related]
5. A Brief Communication on Circulating PD-1-positive T-Regulatory Lymphocytes in Melanoma Patients Undergoing Adjuvant Immunotherapy With Nivolumab.
Gambichler T; Schröter U; Höxtermann S; Susok L; Stockfleth E; Becker JC
J Immunother; 2019 Sep; 42(7):265-268. PubMed ID: 31145230
[TBL] [Abstract][Full Text] [Related]
6. Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma.
Woods DM; Ramakrishnan R; Laino AS; Berglund A; Walton K; Betts BC; Weber JS
Clin Cancer Res; 2018 Dec; 24(24):6236-6247. PubMed ID: 30131384
[TBL] [Abstract][Full Text] [Related]
7. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
[TBL] [Abstract][Full Text] [Related]
8. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
9. Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma.
Liu S; Knochelmann HM; Lomeli SH; Hong A; Richardson M; Yang Z; Lim RJ; Wang Y; Dumitras C; Krysan K; Timmers C; Romeo MJ; Krieg C; O'Quinn EC; Horton JD; Dubinett SM; Paulos CM; Neskey DM; Lo RS
Cell Rep Med; 2021 Oct; 2(10):100411. PubMed ID: 34755131
[TBL] [Abstract][Full Text] [Related]
10. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.
Merhi M; Raza A; Inchakalody VP; Nashwan AJJ; Allahverdi N; Krishnankutty R; Uddin S; Zar Gul AR; Al Homsi MU; Dermime S
Front Immunol; 2018; 9():1769. PubMed ID: 30108590
[TBL] [Abstract][Full Text] [Related]
11. Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab.
Narducci MG; Tosi A; Frezzolini A; Scala E; Passarelli F; Bonmassar L; Monopoli A; Accetturi MP; Cantonetti M; Antonini Cappellini GC; De Galitiis F; Rosato A; Picozza M; Russo G; D'Atri S
Front Immunol; 2020; 11():579894. PubMed ID: 33072126
[TBL] [Abstract][Full Text] [Related]
12. Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma.
Hradska K; Kascak M; Hajek R; Jelinek T
Expert Rev Hematol; 2020 Apr; 13(4):375-392. PubMed ID: 32116068
[No Abstract] [Full Text] [Related]
13. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients.
Kozako T; Yoshimitsu M; Fujiwara H; Masamoto I; Horai S; White Y; Akimoto M; Suzuki S; Matsushita K; Uozumi K; Tei C; Arima N
Leukemia; 2009 Feb; 23(2):375-82. PubMed ID: 18830259
[TBL] [Abstract][Full Text] [Related]
14. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations.
Sato M; Watanabe S; Tanaka H; Nozaki K; Arita M; Takahashi M; Shoji S; Ichikawa K; Kondo R; Aoki N; Hayashi M; Ohshima Y; Koya T; Ohashi R; Ajioka Y; Kikuchi T
PLoS One; 2019; 14(4):e0215292. PubMed ID: 30978241
[TBL] [Abstract][Full Text] [Related]
16. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive immunohistochemical analysis of immune checkpoint molecules in adult T cell leukemia/lymphoma.
Takeuchi M; Miyoshi H; Nakashima K; Kawamoto K; Yamada K; Yanagida E; Muta H; Moritsubo M; Umeno T; Suzuki T; Seto M; Ohshima K
Ann Hematol; 2020 May; 99(5):1093-1098. PubMed ID: 32157421
[TBL] [Abstract][Full Text] [Related]
18. Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy.
Lattanzi M; Deng FM; Chiriboga LA; Femia AN; Meehan SA; Iyer G; Voss MH; Sundatova Y; Huang WC; Balar AV
J Immunother Cancer; 2018 Oct; 6(1):97. PubMed ID: 30285856
[TBL] [Abstract][Full Text] [Related]
19. Development of Acute Adult T-cell Leukemia Following PD-1 Blockade Therapy for Lung Cancer.
Misawa K; Yasuda H; Matsuda H; Hara M; Ochiai T; Koyama D; Takano H; Iwao N; Koike M
Intern Med; 2022; 61(22):3421-3424. PubMed ID: 36385048
[TBL] [Abstract][Full Text] [Related]
20. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
Yoshino K; Nakayama T; Ito A; Sato E; Kitano S
BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
